Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada

A closeup of a stock market ticker
(Pixabay)

> After winning approval for public funding for its CAR-T drug Kymriah in Australia, Novartis announced an agreement for Australian CDMO Cell Therapies to manufacture the therapy in the country. Release  

> CDMO Piramal Pharma Solutions will invest $25 million to add a wing to its Aurora facility in Canada for API manufacturing. Release 

> A £50 million project has been completed to upgrade AstraZeneca’s warehousing, packing and logistics facilities at its site in Macclesfield, U.K. Story 

> Fresenius Kabi is investing €30 million to double the size of a transfusion and apheresis disposables plant in the Dominican Republic. Release  

> Bio-Techne and Wilson Wolf have joined Fresenius Kabi in a joint venture that will focus on providing scalable manufacturing technologies and processes for developing and commercializing cell and gene therapies. Release

Suggested Articles

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.

The FDA knocked a California compounding pharmacy facility for a suite of sanitary concerns, including the presence of ants in the plant.

Merck Animal Health will plow $100 million into its DeSoto, Kansas, plant to scale up production of animal vaccines.